Despite intensive treatments involving months of chemotherapy, surgery and consolidation therapy with life threatening side effects and long-term disabilities, the survival today of children with high-risk NB is less then 40%. Pharmaceutical R&D does not focus on NB because the number of cases does not meet their criteria for commercial development. We are raising funds to drive the research to apply new technologies to precisely identify therapies specific to individual NB patients.
Working closely with physicians who are seeking improved therapies for their NB patients, Cure First will identify novel, targeted and less-toxic treatments. We employ powerful, robotics-based high throughput screening and the ability to inhibit gene function with small RNA molecules to identify targeted treatments in NB cells derived from individual childrens. We will test for thousands of new possible combinations with retinoic acid, which is a relatively non-toxic drug already in use.
We will translate the approach we take for NB to other cancers, and use the power of robotics, genomics and computers to identify personalized, targeted and less-toxic treatments for hundreds of childhood cancers. Our goal is to give children afflicted by NB and their families the chance for a happy life. We have already published promising results for this approach (Toyoshima et al. PNAS, 2012; Cermelli et al, CSH Perspectives in Medicine, 2014; Grandori and Kemp, Future Oncology, 2013).
This project has provided additional documentation in a Microsoft Word file (projdoc.doc).
Dr. Grandori, Cure First founder lecture for scien
Study describing new drug target for neuroblastoma
Cures for cancer, hidden in plain sight?